89 related articles for article (PubMed ID: 2459780)
41. [Various aspects and results of therapy with interferon].
Niederle N
Arzneimittelforschung; 1988 Mar; 38(3A):449-53. PubMed ID: 2456071
[TBL] [Abstract][Full Text] [Related]
42. Present status and future problems of interferon in the treatment of hematological malignancies.
Kimura K
Nihon Ketsueki Gakkai Zasshi; 1985 Dec; 48(8):1677-87. PubMed ID: 2425532
[No Abstract] [Full Text] [Related]
43. Interferon in the treatment of multiple myeloma and the non-Hodgkin's lymphomas.
Wagstaff J; Scarffe JH; Crowther D
Cancer Treat Rev; 1985 Dec; 12 Suppl B():39-44. PubMed ID: 2421896
[No Abstract] [Full Text] [Related]
44. The interferons in haematological malignancies.
Mandelli F; Arcese W; Avvisati G
Baillieres Clin Haematol; 1994 Mar; 7(1):91-113. PubMed ID: 7518713
[TBL] [Abstract][Full Text] [Related]
45. Cytotoxic effect of interferon on primary malignant tumour cells. Studies in various malignancies.
Grandér D; Xu B; Einhorn S
Eur J Cancer; 1993; 29A(14):1940-3. PubMed ID: 7506559
[TBL] [Abstract][Full Text] [Related]
46. Clinical use of biologic response modifiers in cancer treatment: an overview. Part I. The interferons.
Balmer CM
DICP; 1990; 24(7-8):761-8. PubMed ID: 1695795
[TBL] [Abstract][Full Text] [Related]
47. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia.
Talpaz M; McCredie KB; Mavligit GM; Gutterman JU
Blood; 1983 Sep; 62(3):689-92. PubMed ID: 6192858
[TBL] [Abstract][Full Text] [Related]
48. Clinical and immunological studies of human fibroblast interferon.
Ezaki K; Ogawa M; Okabe K; Abe K; Inoue K; Horikoshi N; Inagaki J
Cancer Chemother Pharmacol; 1982; 8(1):47-55. PubMed ID: 6178525
[No Abstract] [Full Text] [Related]
49. Interferon in hematologic malignancies and related disorder.
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-36. PubMed ID: 1695762
[No Abstract] [Full Text] [Related]
50. Interferon therapy in myelomatosis.
Mellstedt H; Aahre A; Bjørkholm M; Cantell K; Holm G; Johansson B; Strander H
Lancet; 1979 Sep; 2(8144):697. PubMed ID: 90788
[No Abstract] [Full Text] [Related]
51. Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.
Tamir A; Jordan WJ; Ritter M; Habib N; Lechler RI; Foster GR; Lombardi G
Clin Exp Immunol; 2005 Dec; 142(3):471-80. PubMed ID: 16297159
[TBL] [Abstract][Full Text] [Related]
52. MHC class I and II antigen expression and interferon alpha treatment of human midgut carcinoid tumors.
Makridis C; Juhlin C; Akerström G; Oberg K; Rastad J
World J Surg; 1994; 18(4):481-6; discussion 486-7. PubMed ID: 7725732
[TBL] [Abstract][Full Text] [Related]
53. Biotherapy in clinical practice.
Figlin RA
Semin Hematol; 1989 Jul; 26(3 Suppl 3):15-24. PubMed ID: 2477904
[TBL] [Abstract][Full Text] [Related]
54. [Current status of interferon therapy].
Dittrich C
Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
[TBL] [Abstract][Full Text] [Related]
55. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
56. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
[TBL] [Abstract][Full Text] [Related]
57. The role of interferons in the treatment of hematologic malignancies.
Gutterman JU
Semin Hematol; 1988 Jul; 25(3 Suppl 3):3-8. PubMed ID: 2459780
[TBL] [Abstract][Full Text] [Related]
58. Biotherapy with interferon--1988.
Figlin RA
Semin Oncol; 1988 Dec; 15(6 Suppl 6):3-9. PubMed ID: 2462749
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
